Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2004

01-05-2004 | Image of the Month

Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT

Authors: Alexander Matthies, Samer Ezziddin, Eva-Maria Ulrich, Holger Palmedo, Hans-Jürgen Biersack, Hans Bender, Stefan Guhlke

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2004

Login to get access

Excerpt

Fluorine-18 fluoroacetate [1] appears to be an interesting alternative to 11C-acetate [2, 3] for imaging prostate cancer with PET. We acquired the first 18F-fluoroacetate PET images in a patient with prostate cancer, rising PSA (101 ng/ml) and progressive bone metastases. Scanning started 70 min after i.v. injection of 280 MBq 18F-fluoroacetate using a combined PET/CT system (Siemens Biograph). …
Literature
1.
Ponde DE, Oyama N, Dence CS, Welch MJ.18F-fluoroacetate, an analogue of C-11 acetate for tumour imaging [abstract]. J Nucl Med 2003; 44:1062.
2.
Oyama N, Miller TR, Dehdashti F, et al.11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44:549–555.
3.
Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30:607–611.
Metadata
Title
Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT
Authors
Alexander Matthies
Samer Ezziddin
Eva-Maria Ulrich
Holger Palmedo
Hans-Jürgen Biersack
Hans Bender
Stefan Guhlke
Publication date
01-05-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1437-1

Other articles of this Issue 5/2004

European Journal of Nuclear Medicine and Molecular Imaging 5/2004 Go to the issue

Original Article

Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship

Original Article

Long-term prognostic value of exercise 99mTc-MIBI SPET myocardial perfusion imaging in patients after percutaneous coronary intervention

Letter to the Editor

Differences in SPET analysis of thyroid-associated orbitopathy

Original Article

Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET

Original Article

The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis

Controversies—For

Is 11C-choline the most appropriate tracer for prostate cancer?